NCT02845375View on ClinicalTrials.gov

Effect of Neuromuscular Blockade and Reversal on Breathing

PHASE4CompletedINTERVENTIONAL
Enrollment

46

Participants

Timeline

Start Date

September 1, 2016

Primary Completion Date

September 1, 2018

Study Completion Date

September 1, 2018

Conditions
Respiratory Insufficiency
Interventions
DRUG

Sugammadex

Sugammadex will be administered following a period of muscle relaxation after wich respiratory measurements will be obtained.

DRUG

Neostigmine

Neostigmine will be administered following a period of muscle relaxation after wich respiratory measurements will be obtained.

DRUG

Placebo

Placebo will be administered following a period of muscle relaxation after wich respiratory measurements will be obtained.

Trial Locations (1)

2333 ZA

Leiden University Medical Center, Leiden

All Listed Sponsors
lead

Leiden University Medical Center

OTHER

NCT02845375 - Effect of Neuromuscular Blockade and Reversal on Breathing | Biotech Hunter | Biotech Hunter